analytical characterisation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-05 and is reviewed periodically as new material appears.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved in the US, EU and Australia | Sale and import restricted; no licensed product |
| Typical test matrices | Urine, serum, seized powder | Urinary detection window is short |
| Primary identification method | LC-MS/MS against a reference standard | High-resolution mass used for confirmation |
| Data sources in the literature | Small trials, case reports, pharmacovigilance | No registrational trial dataset exists |
| Common marketing names | Melanotan 2, MT-II, MT-2 | Label content may not match declared peptide |
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Immune response – Nuclear actin polymerizes upon T-cell receptor stimulation and is required for cytokine expression and antibody production in vivo. DNA repair – Nuclear actin mediates the repair of DNA double-strand breaks. In the cell nucleus, a filamentous polymer of actin (F-actin) acts both in the DNA repair pathway of non homologous end joining and in the pathway of homologous recombinational repair. Due to its ability to undergo conformational changes and interaction with many proteins, actin acts as a regulator of formation and activity of protein complexes such as transcriptional complex.
=== FSEC-TS === In fluorescence-detection size exclusion chromatography the protein of interest is fluorescently tagged (e.g., with GFP) and run through a gel filtration column on an FPLC system equipped with a fluorescence detector. The resulting chromatogram allows the researcher to estimate the dispersity and expression level of the tagged protein in the current buffer. Since only fluorescence is measured, only the tagged protein is seen in the chromatogram. FSEC is typically used to compare membrane protein orthologs or screen detergents to solubilize specific membrane proteins in. For fluorescence-detection size-exclusion chromatography-based thermostability assay (FSEC-TS) the samples are heated in the same manner as in FastPP and CETSA and following centrifugation to clear away precipitate the supernatant is treated in the same manner as FSEC. Larger aggregates are seen in the void volume while the peak height for the protein of interest decreases when the unfolding temperature is reached. GFP has a Tm of ~76 °C so the technique is limited to temperature below ~70 °C.
== Diseases in aquatic animals == Bacillus cereus group bacteria, notably B. cereus and B. thuringiensis, are also pathogenic to multiple aquatic organisms including Chinese softshell turtle (Pelodiscus sinensis), causing infection characterized by gross lesions such as hepatic congestion and enlarged spleen with high mortality.
Sources: en.wikipedia.org
=== Vaccines === Vaccines are an essential part of the response to reduce AMR as they prevent infections, reduce the use and overuse of antimicrobials, and slow the emergence and spread of drug-resistant pathogens. Microorganisms usually do not develop resistance to vaccines because vaccines reduce the spread of the infection and target the pathogen in multiple ways in the same host and possibly in different ways between different hosts. Furthermore, if the use of vaccines increases, there is evidence that antibiotic resistant strains of pathogens will decrease; the need for antibiotics will naturally decrease as vaccines prevent infection before it occurs. A 2024 report by WHO finds that vaccines against 24 pathogens could reduce the number of antibiotics needed by 22% or 2.5 billion DDD every year. If vaccines could be rolled out against all the evaluated pathogens, they could save a third of the hospital costs associated with AMR. Vaccinated people have fewer infections and are protected against potential complications from secondary infections that may need antimicrobial medicines or require admission to hospital. However, there are well documented cases of vaccine resistance, although these are usually much less of a problem than antimicrobial resistance. Antistaphylococcal vaccines have shown limited efficacy, because of immunological variation between Staphylococcus species, and the limited duration of effectiveness of the antibodies produced. Development and testing of more effective vaccines is underway.
The drug is a controlled substance in many countries, so non-medical use for purposes such as improving physique and performance has been generally illicit. In the United States, the FDA's Endocrinologic and Metabolic Drugs Advisory Committee unanimously concluded in 1984 that there was no evidence of efficacy for oxandrolone. On March 26, 2019, Gemini asked FDA to withdraw approval for all doses of the drug, stating that they were no longer marketing it. FDA notified Gemini and other license holders on December 16, 2022, that it believed that the potential problems with the drug that the drug were sufficiently serious that it should be removed from the market, citing the 1984 finding of lack of efficacy and the extensive safety warnings and precautions listed on the prescribing information, "including peliosis hepatis, sometimes associated with liver failure and intra-abdominal hemorrhage; liver cell tumors, sometimes fatal; and blood lipid changes that are known to be associated with increased risk of atherosclerosis" as well as "cholestatic hepatitis, hypercalcemia in patients with breast cancer, and increased risk for the development of prostatic hypertrophy and prostatic carcinoma in geriatric patients." Gemini and Sandoz requested that the FDA completely withdraw approval for the drug.
The Black Mesa Research Facility (also simply called Black Mesa) is a fictional large underground laboratory complex that serves as the primary setting for the video game Half-Life and its expansions, as well as its unofficial remake, Black Mesa. It also features in the wider Half-Life universe, including the Portal series. Located in the New Mexico desert in a decommissioned Cold War missile site, it is the former employer of Half-Life's theoretical physicist protagonist, Gordon Freeman, and a competitor of Aperture Science. While the facility ostensibly conducts military-industrial research, its secret experiments into teleportation have caused it to make contact with the alien world of Xen, and its scientists covertly study its life-forms and materials. In a catastrophic event known as the "Black Mesa Incident", an "anti-mass spectrometer" experiment conducted on Xen matter causes a Resonance Cascade disaster that allows aliens to invade Earth, and is the catalyst for the events of the series. Half-Life was critically acclaimed for its storytelling and level design. At the time, the integration of narrative into gameplay through scripted sequences and NPCs instead of through cutscenes was considered groundbreaking for a first-person shooter.
He also stated that the novel "historicizes and theorizes animal life and death," and that it demonstrates the ways that symbolism and materiality of meat are "co-opted within patriarchal political structures," putting it in the same space as theorists like Carol J. Adams, Donna J. Haraway, Laura Wright, and Cary Wolfe, and writers such as J. M. Coetzee. In 1997, S. Reneé Wheeler wrote in the Vegetarian Journal, saying that "finding books with vegetarian themes" is important for helping children "feel legitimate in being vegetarian." In 2004, writer J. M. Coetzee argued that since the "mode of consciousness of nonhuman species is quite different from human consciousness," it is hard for writers to realize this for animals, with a "temptation to project upon them feelings and thoughts that may belong only to our own human mind and heart," and stated that reviewers have ignored the presence of animals in his books. He also stated that animals are present in his "fiction either not at all or in a merely subsidiary role" because they occupy "a subsidiary place in our lives" and argued that it is not "possible to write about the inner lives of animals in any complex way." In 2014, The New Yorker published a short story by Jonathan Lethem titled "Pending Vegan" which follows "one family, a husband and wife and their four-year-old twin daughters" on a trip to SeaWorld in San Diego, California.
Sources: en.wikipedia.org
==== United nations ==== The UN Commission on Narcotic Drugs added 2C-B to Schedule II of the Convention on Psychotropic Substances in March 2001. 2C-B is a scheduled drug in most jurisdictions. The following is a partial list of territories where the substance has been scheduled.
==== Medical and research uses ==== Radium (usually in the form of radium chloride or radium bromide) was used in medicine to produce radon gas, which in turn was used as a cancer treatment. Several of these radon sources were used in Canada in the 1920s and 1930s. However, many treatments that were used in the early 1900s are not used anymore because of the harmful effects radium bromide exposure caused. Some examples of these effects are anaemia, cancer, and genetic mutations. As of 2011, safer gamma emitters such as 60Co, which is less costly and available in larger quantities, are usually used to replace the historical use of radium in this application, but factors including increasing costs of cobalt and risks of keeping radioactive sources on site have led to an increase in the use of linear particle accelerators for the same applications. In the U.S., from 1940 through the 1960s, radium was used in nasopharyngeal radium irradiation, a treatment that was administered to children to treat hearing loss and chronic otitis. The procedure was also administered to airmen and submarine crew to treat barotrauma. Early in the 1900s, biologists used radium to induce mutations and study genetics. As early as 1904, Daniel MacDougal used radium in an attempt to determine whether it could provoke sudden large mutations and cause major evolutionary shifts. Thomas Hunt Morgan used radium to induce changes resulting in white-eyed fruit flies.
== Adverse reactions == Sleeping pills, including zopiclone, have been associated with an increased risk of death. The British National Formulary states adverse reactions as follows: "taste disturbance (some report a metallic taste); less commonly nausea, vomiting, dizziness, drowsiness, dry mouth, headache; rarely amnesia, confusion, depression, hallucinations, nightmares; very rarely light-headedness, incoordination, paradoxical effects [...] and sleep-walking also reported". Long-term use of Z-drugs, including zopiclone, has been associated with dependence, withdrawal symptoms, and cognitive impairment.
== Comparisons to vertebrates == This open system might appear to be inefficient compared to the closed circulatory systems of the vertebrates, but the two systems have very different demands placed on them. In vertebrates, the circulatory system is responsible for transporting oxygen to all the tissues and removing carbon dioxide from them. It is this requirement that establishes the level of performance demanded of the system. The efficiency of the vertebrate system is far greater than is needed for transporting nutrients, hormones, and so on; whereas in insects, exchange of oxygen and carbon dioxide occurs in the tracheal system. Hemolymph plays no part in the process in most insects. Only in a few insects living in low-oxygen environments are there hemoglobin-like molecules that bind oxygen and transport it to the tissues. Therefore, the demands placed upon the system are much lower. Some arthropods and most molluscs possess the copper-containing hemocyanin, however, for oxygen transport.
The Bull's Head Tavern was noted for George Washington's having stopped there for refreshment before riding down to the waterfront to witness the departure of British troops in 1783. Leading to the Post Road, the main route to Boston, the Bowery rivaled Broadway as a thoroughfare; as late as 1869, when it had gained the "reputation of cheap trade, without being disreputable" it was still "the second principal street of the city".
Sources: en.wikipedia.org
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.
Reversed-phase LC-MS/MS is the usual approach for both identification and quantitation. High-resolution mass spectrometry and peptide mapping serve as confirmatory methods. Immunoassays are rarely used alone because of cross-reactivity.
Published testing of seized and purchased samples frequently reports discrepancies between declared and measured peptide content. Counter-ion content and residual solvents add further variation. Independent analysis is the only way to confirm composition.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.